Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Controlled, Open-label Phase IIb Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
Conditions
Interventions
HH-003(20mg/kg)
HH-003(10mg/kg)
+1 more
Locations
1
China
Beijing Ditan Hospital Captial Medical University
Beijing, Beijing Municipality, China
Start Date
June 16, 2023
Primary Completion Date
July 18, 2024
Completion Date
June 21, 2025
Last Updated
March 27, 2026
Lead Sponsor
Huahui Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions